Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Opko Health Inc (OPK)

Opko Health Inc (OPK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,176,951
  • Shares Outstanding, K 669,831
  • Annual Sales, $ 901,940 K
  • Annual Income, $ -314,930 K
  • 60-Month Beta 2.06
  • Price/Sales 2.35
  • Price/Cash Flow N/A
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.04
  • Number of Estimates 3
  • High Estimate 0.04
  • Low Estimate 0.04
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +136.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.84 +11.27%
on 09/04/20
4.85 -34.85%
on 08/24/20
-1.70 (-34.98%)
since 08/21/20
3-Month
2.51 +25.90%
on 06/25/20
6.47 -51.16%
on 07/21/20
+0.53 (+20.15%)
since 06/22/20
52-Week
1.12 +182.88%
on 04/03/20
6.47 -51.16%
on 07/21/20
+1.14 (+56.44%)
since 09/20/19

Most Recent Stories

More News
AngioDynamics Unveils Auryon Atherectomy System for PAD

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

ANGO : 9.84 (-0.81%)
SRDX : 38.07 (-1.37%)
MMSI : 41.52 (-1.05%)
OPK : 3.16 (-2.77%)
Accuray's Radixact With Synchrony Used in Japan Hospitals

The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.

ARAY : 2.51 (-3.83%)
SRDX : 38.07 (-1.37%)
MMSI : 41.52 (-1.05%)
OPK : 3.16 (-2.77%)
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 55.98 (-0.27%)
REGN : 561.33 (+1.01%)
AMGN : 244.25 (+0.44%)
IBB : 132.45 (-0.29%)
OPK : 3.16 (-2.77%)
XBI : 111.24 (-0.71%)
DexCom Introduces Registry to Monitor Outcomes of G6 System

DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.

DXCM : 387.23 (-1.14%)
SRDX : 38.07 (-1.37%)
MMSI : 41.52 (-1.05%)
OPK : 3.16 (-2.77%)
Here's Why You Should Retain Avanos Medical Stock for Now

Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.

SRDX : 38.07 (-1.37%)
MMSI : 41.52 (-1.05%)
OPK : 3.16 (-2.77%)
AVNS : 33.21 (+0.58%)
Diagnostic Devices Give the Healthcare System New Avenues for Innovation

, /PRNewswire/ -- The recent pandemic, which has put a heavy toll on our economy and pushed the healthcare system into a severe scarcity problem, further illustrates the importance of medical devices...

OPK : 3.16 (-2.77%)
NMRD : 3.61 (-1.10%)
IBIO : 2.29 (-5.76%)
CODX : 15.28 (+0.73%)
NVAX : 109.21 (-0.85%)
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy

OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.

RHHBY : 46.1700 (-0.28%)
INCY : 85.26 (-0.15%)
LLY : 149.49 (-1.12%)
OPK : 3.16 (-2.77%)
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know

OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -0.63% move from the prior day.

OPK : 3.16 (-2.77%)
Here's Why You Should Add Surmodics to Your Portfolio Now

Investor confidence is high on Surmodics (SRDX) stock, thanks to solid prospects.

SRDX : 38.07 (-1.37%)
MMSI : 41.52 (-1.05%)
OPK : 3.16 (-2.77%)
NXGN : 12.13 (-2.73%)
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients

OPKO Health, Inc. (NASDAQ: OPK) announces the initiation of a Phase 2 trial with RAYALDEE as a treatment for mild-to-moderate COVID-19. The trial, "A Randomized, Double-Blind Placebo-Controlled Study...

OPK : 3.16 (-2.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade OPK with:

Business Summary

OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.

See More

Key Turning Points

2nd Resistance Point 3.45
1st Resistance Point 3.35
Last Price 3.16
1st Support Level 3.12
2nd Support Level 2.99

See More

52-Week High 6.47
Fibonacci 61.8% 4.43
Fibonacci 50% 3.79
Fibonacci 38.2% 3.16
Last Price 3.16
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar